Follow
Hesham Al-Sallami
Hesham Al-Sallami
School of Pharmacy, University of Otago
Verified email at otago.ac.nz - Homepage
Title
Cited by
Cited by
Year
Prediction of fat-free mass in children
HS Al-Sallami, A Goulding, A Grant, R Taylor, N Holford, SB Duffull
Clinical pharmacokinetics 54, 1169-1178, 2015
1332015
Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol
A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, TK Mukkur, ...
Drug design, development and therapy, 1221-1230, 2014
772014
Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
R Negrulj, A Mooranian, N Chen-Tan, HS Al-Sallami, M Mikov, ...
Artificial cells, nanomedicine, and biotechnology 44 (5), 1290-1297, 2016
592016
Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study
A Mooranian, R Negrulj, N Chen-Tan, HS Al-Sallami, Z Fang, T Mukkur, ...
Drug design, development and therapy, 1003-1012, 2014
562014
Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes
A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ...
Aaps Pharmscitech 16, 45-52, 2015
522015
Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming Staphylococcus aureus Bovine Mastitis Isolates: A Pilot Study …
J Gogoi-Tiwari, V Williams, CB Waryah, P Costantino, H Al-Salami, ...
PLoS One 12 (1), e0170668, 2017
512017
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
A Mooranian, R Negrulj, HS Al-Sallami, Z Fang, M Mikov, ...
Journal of microencapsulation 32 (2), 151-156, 2015
472015
Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study
A Mooranian, S Raj Wagle, B Kovacevic, R Takechi, J Mamo, V Lam, ...
Scientific Reports 10 (1), 106, 2020
462020
The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti …
A Mooranian, R Negrulj, R Takechi, J Mamo, H Al-Sallami, H Al-Salami
Drug delivery and translational research 8, 543-551, 2018
422018
Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 …
A Mooranian, N Zamani, R Takechi, H Al-Sallami, M Mikov, ...
Artificial Cells, Nanomedicine, and Biotechnology 46 (sup3), 748-754, 2018
342018
Between-subject variability: should high be the new normal?
HS Al-Sallami, SL Cheah, SY Han, J Liew, J Lim, MA Ng, H Solanki, ...
European journal of clinical pharmacology 70, 1403-1404, 2014
322014
The time course of drug effects
HS Al‐Sallami, VV Pavan Kumar, CB Landersdorfer, JB Bulitta, SB Duffull
Pharmaceutical Statistics: The Journal of Applied Statistics in the …, 2009
292009
Newborn vitamin K prophylaxis: a historical perspective to understand modern barriers to uptake
A Majid, M Blackwell, RS Broadbent, DP Barker, HS Al-Sallami, ...
Hospital Pediatrics 9 (1), 55-60, 2019
222019
Choosing the allometric exponent in covariate model building
J Sinha, HS Al-Sallami, SB Duffull
Clinical Pharmacokinetics 58, 89-100, 2019
212019
Dabigatran: rational dose individualisation and monitoring guidance is needed
SB Duffull, DFB Wright, HS Al-Sallami, PJ Zufferey, JM Faed
The New Zealand Medical Journal (Online) 125 (1357), 2012
212012
A framework for simplification of quantitative systems pharmacology models in clinical pharmacology
A Derbalah, H Al‐Sallami, C Hasegawa, A Gulati, SB Duffull
British Journal of Clinical Pharmacology 88 (4), 1430-1440, 2022
202022
Revisiting the pharmacology of unfractionated heparin
A Derbalah, S Duffull, F Newall, K Moynihan, H Al-Sallami
Clinical Pharmacokinetics 58 (8), 1015-1028, 2019
192019
A review of the methods and associated mathematical models used in the measurement of fat-free mass
J Sinha, SB Duffull, HS Al-Sallami
Clinical Pharmacokinetics 57, 781-795, 2018
192018
The Influence of Dosing Time, Variable Compliance and Circadian Low‐Density Lipoprotein Production on the Effect of Simvastatin: Simulations from a Pharmacokinetic …
DFB Wright, VV Pavan Kumar, HS Al‐Sallami, SB Duffull
Basic & clinical pharmacology & toxicology 109 (6), 494-498, 2011
182011
Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins
HS Al-Sallami, MA Barras, B Green, SB Duffull
Clinical pharmacokinetics 49, 567-571, 2010
182010
The system can't perform the operation now. Try again later.
Articles 1–20